Serum Obestatin: A Biomarker of Cardiovascular and All-Cause Mortality in Hemodialysis Patients.

CONCLUSION: Serum obestatin behaves as a biomarker for cardiovascular and all-cause mortality in MHD patients. The prognostic ability of obestatin in this regard is independent of inflammation, nutritional status, acyl-ghrelin's and adipokines' activity and is modified by age being very prominent in patients older than 71 years.
PMID: 29694945 [PubMed - as supplied by publisher]

Source: American Journal of Nephrology - April 25, 2018 Category: Urology & Nephrology Authors: Beberashvili I, Katkov A, Sinuani I, Azar A, Shapiro G, Feldman L, Gorelik O, Stav K, Efrati S Tags: Am J Nephrol Source Type: research